Policy Title: Parsabiv (etelcalcetide) (intravenous)

<table>
<thead>
<tr>
<th>Department: PHA</th>
</tr>
</thead>
</table>

Effective Date: 06/01/2020

Review Date: 03/18/2020, 06/10/2021

Purpose: To support safe, effective and appropriate use of Parsabiv (etelcalcetide).

Scope: Medicaid, Commercial, Medicare-Medicaid Plan (MMP)

Policy Statement:
Parsabiv (etelcalcetide) is covered under the Medical Benefit when used within the following guidelines. Use outside of these guidelines may result in non-payment unless approved under an exception process.

Procedure:
Coverage of Parsabiv (etelcalcetide) will be reviewed prospectively via the prior authorization process based on criteria below.

Initial Criteria:
- The patient is ≥ 18 years of age; AND
- The patient has a diagnosis of hyperthyroidism secondary to chronic kidney disease; AND
- The patient is receiving hemodialysis; AND
- Documentation of serum calcium (corrected for albumin) ≥8.4 mg/dL; AND
- Documentation of pre-treatment parathyroid hormone level >400 pg/mL; AND
- The patient is not receiving dual therapy with a calcium-sensing receptor agonist; AND
- The patient has a documented failure, contraindication or ineffective response at maximum tolerated doses to Sensipar; AND
- Dosing is in accordance with the United States Food and Drug Administration approved labeling;
- MMP members who have previously received this medication within the past 365 days are not subject to Step Therapy Requirements.

Continuation of Therapy Criteria:
- Patient is tolerating treatment; AND
- The patient has a diagnosis of hyperthyroidism secondary to chronic kidney disease; AND
- The patient is receiving hemodialysis; AND
• Documentation of a reduction in serum calcium (corrected for albumin) from baseline; AND
• The patient is not receiving dual therapy with a calcium-sensing receptor agonist; AND
• Dosing is in accordance with the United States Food and Drug Administration approved labeling

Coverage durations:
• Initial coverage: 6 months
• Continuation of therapy coverage: 6 months

*** Requests will also be reviewed to National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) if applicable.***

Dosage/Administration:

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
<th>Maximum dose (1 billable unit = 0.1 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary hyperparathyroidism</td>
<td>2.5-15 mg three times a week</td>
<td>150 billable units three times a week</td>
</tr>
</tbody>
</table>

Investigational use: All therapies are considered investigational when used at a dose or for a condition other than those that are recognized as medically accepted indications as defined in any one of the following standard reference compendia: American Hospital Formulary Service Drug information (AHFS-DI), Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs, or Peer-reviewed published medical literature indicating that sufficient evidence exists to support use. Neighborhood does not provide coverage for drugs when used for investigational purposes.

Applicable Codes:
Below is a list of billing codes applicable for covered treatment options. The below tables are provided for reference purposes and may not be all-inclusive. Requests received with codes from tables below do not guarantee coverage. Requests must meet all criteria provided in the procedure section.

The following HCPCS/CPT codes are:

<table>
<thead>
<tr>
<th>HCPCS/CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0606</td>
<td>Injection, eteocalcetide, 0.1mg</td>
</tr>
</tbody>
</table>

References: